SCHEMBL8007285

SCHEMBL8007285

NC(N)[CH]c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.41
ALDH1A1 P00352 2/20 0.41
DPP4 P27487 2/20 0.41
MAOB P27338 2/20 0.41
TSHR P16473 1/20 0.41
F2 P00734 1/20 0.41
CYP2A6 P11509 1/20 0.41
CYP19A1 P11511 1/20 0.40
MAOA P21397 1/20 0.40
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
EPHX1 P07099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7572963 0.78 HTR2A (0.48) HTR2AALDH1A1CYP2A6MAOALMNA
SCHEMBL6048471 0.78 ALDH1A1 (0.43) HTR2AALDH1A1DPP4MAOBTSHR
SCHEMBL3511627 0.76 DPP4 (0.48) HTR2ADPP4F2LMNA
SCHEMBL20915029 0.76 DPP4 (0.48) HTR2ADPP4F2LMNA
SCHEMBL28772606 0.76 DPP4 (0.48) HTR2ADPP4F2LMNA
SCHEMBL2594007 0.74 ALDH1A1 (0.46) HTR2AALDH1A1DPP4MAOBTSHR
SCHEMBL3647646 0.72 HTR2A (0.35) HTR2AALDH1A1DPP4MAOBTSHR
SCHEMBL9960125 0.72 MAOB (0.50) HTR2AALDH1A1MAOBCYP19A1MAOA
SCHEMBL315078 0.71 HTR2A (0.41) HTR2AALDH1A1MAOBTSHRCYP2A6
SCHEMBL184701 0.71 ALDH1A1 (0.41) ALDH1A1MAOBTSHRCYP2A6CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0763016-B1 COMPOSITIONS AND METHODS FOR TREATING MAST-CELL MEDIATED CONDITIONS AXYS PHARM INC (US) 2000-01-26 EP claimed
EP-0763016-B1 COMPOSITIONS AND METHODS FOR TREATING MAST-CELL MEDIATED CONDITIONS AXYS PHARM INC (US) 2000-01-26 EP disclosed
EP-0763016-A1 COMPOSITIONS AND METHODS FOR TREATING MAST-CELL MEDIATED CONDITIONS ARRIS PHARMACEUTICAL CORPORATION (US) 1997-03-19 EP disclosed
WO-1995032945-A1 COMPOSITIONS AND METHODS FOR TREATING MAST-CELL MEDIATED CONDITIONS ARRIS PHARMACEUTICAL CORPORATION (US) 1995-12-07 WO disclosed